Longeveron Inc. (LGVN )
Currency in USD Disclaimer
Subscribe Now for Delta3 AI Alerts
Don’t miss out on top stock picks and market insights. Subscribe to Delta3 AI Alerts for real-time updates and expert analysis straight to your inbox. Stay informed and maximize your investment potential.
Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
- Symbol LGVN
- Company Longeveron Inc.
- Price $2.71
- Changes Percentage -59.43
- Change -3.97
- Day Low $2.7
- Day High $3.35
- Year High $1.23
- Year Low $0.48
- Market Cap $16,842,597
- Price Avg 50 EMA (D) $0.71
- Price Avg 200 EMA (D) $0.72
- Exchange NASDAQ
- Volume 768,599
- Average Volume 344,280
- Open $3.14
- Previous Close $6.68
- EPS -0.99
- PE -0.85
- Earnings Announcement 2026-11-03 05:00:00
- Shares Outstanding $19,934,426
Company brief: LONGEVERON INC. (LGVN )
- Healthcare
- Biotechnology
- Mr. Mohamed Wa'el Ahmed Hashad
- https://www.longeveron.com
- US
- N/A
- 02-12-2021
- US54303L1044
Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions. The company's lead investigational product is the LOMECEL-B, a cell-based therapy product that is derived from culture-expanded medicinal signaling cells that are sourced from bone marrow of young healthy adult donors. It is conducting Phase 1 and 2 clinical trials in various indications, such as aging frailty, alzheimer's disease, metabolic syndrome, acute respiratory distress syndrome, and hypoplastic left heart syndrome. The company was incorporated in 2014 and is based in Miami, Florida.